BI and Tsinghua to Use Immunology for New Infectious Disease Drugs

Boehringer Ingelheim and Tsinghua University will collaborate to discover and develop immunological therapies for infectious diseases, particularly for tuberculosis and chronic hepatitis B, which remain problems in China. As in immuno-oncology, the effort will seek to activate the innate immune system. Although vaccines have lowered the effect of infectious diseases, infections are developing resistance to anti-microbial treatments. Bacterial/viral pneumonia and tuberculosis remain a leading cause of death globally. More details....

Share this with colleagues:

Original Article: BI and Tsinghua to Use Immunology for New Infectious Disease Drugs

More From BioPortfolio on "BI and Tsinghua to Use Immunology for New Infectious Disease Drugs"